Synergistic effect and molecular mechanisms of traditional Chinese medicine on regulating tumor microenvironment and cancer cells

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Xu, Jingnan ^a,b   Song, Zhuo ^a   Guo, Qiujun ^a,b   Li, Jie ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; PROGRAMMED DEATH 1 RECEPTOR; SORAFENIB; HERBACEOUS AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENICITY; CELL HYPOXIA; CHINESE MEDICINE; DRUG MECHANISM; DRUG POTENTIATION; EXTRACELLULAR MATRIX; HUMAN; LIVER CELL CARCINOMA; LYMPHANGIOGENESIS; METASTASIS INHIBITION; NONHUMAN; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; THERAPY EFFECT; TUMOR IMMUNITY; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; DRUG EFFECTS; GENETICS; NEOPLASMS; PATHOLOGY;

DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84962034288     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/1490738     Document Type: Review

References (149)

1. F. Seretis, C. Seretis, H. Youssef, and M. Chapman, "Colorectal cancer: seed and soil hypothesis revisited, " Anticancer Research, vol. 34, no. 5, pp. 2087-2094, 2014.
2. I. J. Fidler, "The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited, " Nature Reviews Cancer, vol. 3, no. 6, pp. 453-458, 2003.
3. J. Diao, J. Zhao, E. Winter, and M. S. Cattral, "Tumors suppress in situ proliferation of cytotoxic T cells by promoting differentiation of Gr-1+ conventional dendritic cells through IL-6, " The Journal of Immunology, vol. 186, no. 9, pp. 5058-5067, 2011.
4. O. Oluwadara, L. Giacomelli, X. Brant, et al., "The role of the microenvironment in tumor immune surveillance, " Bioinformation, vol. 5, no. 7, pp. 285-290, 2011.
5. S. Chabot, N. Jabrane-Ferrat, K. Bigot, et al., "A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor, "The Journal of Experimental Medicine, vol. 208, no. 5, pp. 973-986, 2011.
6. E. T. Shinohara and A. Maity, "Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment, " Current Molecular Medicine, vol. 9, no. 9, pp. 1034-1045, 2009.
7. P. Lu, W. Su, Z.-H. Miao, H.-R. Niu, J. Liu, and Q.-L. Hua, "Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer, " Chinese Journal of Integrative Medicine, vol. 14, no. 1, pp. 33-36, 2008.
8. B. Wang and J. Cui, "Treatment of mid-late stage NSCLC using sodiumcantharidinate/vitamin B6/GP regimen in clinic, " Journal of Cancer Research and Therapeutics, vol. 10, no. 5, pp. 79-81, 2014.
9. L. Guo, S.-P. Bai, L. Zhao, and X.-H. Wang, "Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival, " Medical Oncology, vol. 29, no. 3, pp. 1656-1662, 2012.
10. L. W. Ruan and Y. C. Deng, "Study on effect of Xiaoaiping in enhancing efficacy of neoadjuvant chemotherapy for breast cancer and its mechanism, " Zhongguo Zhong Yao Za Zhi, vol. 40, no. 4, pp. 749-752, 2015.
11. Y. Liu, Z. W. Jia, L. Dong, R. Wang, and G. Q. Qiu, "A randomized pilot study of atractylenolide I on gastric cancer cachexia patients, " Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 3, pp. 337-344, 2008.
12. C. Zhong, H.-D. Li, D.-Y. Liu, et al., "Clinical study of hepatectomy combined with Jianpi HuayuTherapy for hepatocellular carcinoma, " Asian Pacific Journal of Cancer Prevention, vol. 15, no. 14, pp. 5951-5957, 2014.
13. T.-J. Qin, X.-H. Zhao, J. Yun, L.-X. Zhang, Z.-P. Ruan, and B.-R. Pan, "Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma, " World Journal of Gastroenterology, vol. 14, no. 33, pp. 5210-5216, 2008.
14. M. I. James, C. Iwuji, G. Irving, et al., "Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy, " Cancer Letters, vol. 364, no. 2, pp. 135-141, 2015.
15. D.-R. Lu, D.-Y. Li, X.-Y. Chen, P.-Z. Ye, and S.-D. Tian, "Clinical research of compound Zhebei granules for increasing the therapeutic effect of chemotherapy in refractory acute leukemia patients, " Journal of Traditional Chinese Medicine, vol. 29, no. 3, pp. 190-194, 2009.
16. Y. Jia, Q. Guan, Y. Guo, and C. Du, "Reduction of inflammatory hyperplasia in the intestine in colon cancer-prone mice by water-extract of Cistanche deserticola, " Phytotherapy Research, vol. 26, no. 6, pp. 812-819, 2012.
17. Y. Sun, "Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures, " Medicinal Research Reviews, vol. 35, no. 2, pp. 408-436, 2015.
18. J. Li, L. Li, R. Liu, and H.-S. Lin, "Establishing Chinesemedicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology, " Chinese Journal of Integrative Medicine, vol. 18, no. 10, pp. 730-736, 2012.
19. M. W. Pickup, J. K. Mouw, and V. M. Weaver, "The extracellular matrix modulates the hallmarks of cancer, " EMBO Reports, vol. 15, no. 12, pp. 1243-1253, 2014.
20. P. Lu, V. M. Weaver, and Z. Werb, "The extracellular matrix: a dynamic niche in cancer progression, " The Journal of Cell Biology, vol. 196, no. 4, pp. 395-406, 2012.
21. M. Giussani, G. Merlino, V. Cappelletti, E. Tagliabue, and M. G. Daidone, "Tumor-extracellular matrix interactions: identification of tools associated with breast cancer progression, " Seminars in Cancer Biology, vol. 35, pp. 3-10, 2015.
22. A. W. Holle, J. L. Young, and J. P. Spatz, "In vitro cancer cell-ECM interactions inform in vivo cancer treatment, " Advanced Drug Delivery Reviews, vol. 97, pp. 270-279, 2016.
23. C. A. Sherman-Baust, A. T. Weeraratna, L. B. A. Rangel, et al., "Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells, " Cancer Cell, vol. 3, no. 4, pp. 377-386, 2003.
24. W. Deng, H. Sui, Q. Wang, et al., "AChinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathways, " BMC Complementary and Alternative Medicine, vol. 13, article 65, 2013.
25. R. Zhou, L. Xu, M. Ye, M. Liao, H. Du, and H. Chen, "Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways, " Hormone and Metabolic Research, vol. 46, no. 11, pp. 753-760, 2014.
26. L. Zheng, Y.-M. Zhang, Y.-Z. Zhan, and C.-X. Liu, "Momordica cochinchinensis seed extracts suppress migration and invasion of human breast cancer ZR-75-30 cells via down-regulating MMP-2 and MMP-9, " Asian Pacific Journal of Cancer Prevention, vol. 15, no. 3, pp. 1105-1110, 2014.
27. G. Kroemer, G. Marino, and B. Levine, "Autophagy and the integrated stress response, " Molecular Cell, vol. 40, no. 2, pp. 280-293, 2010.
28. P. Vaupel, M. Hockel, and A. Mayer, "Detection and characterization of tumor hypoxia using pO2 histography, " Antioxidants and Redox Signaling, vol. 9, no. 8, pp. 1221-1235, 2007.
29. J. L. Yu, J. W. Rak, B. L. Coomber, D. J. Hicklin, and R. S. Kerbel, "Effect of p53 status on tumor response to antiangiogenic therapy, " Science, vol. 295, no. 5559, pp. 1526-1528, 2002.
30. X. Yang, D.-D. Yu, F. Yan, et al., "The role of autophagy induced by tumor microenvironment in different cells and stages of cancer, " Cell & Bioscience, vol. 5, article 14, 2015.
31. Z. Zhou, H. Liu, X. Chi, et al., "Aprotein-corona-free 1-2 dualmodal contrast agent for accurate imaging of lymphatic tumor metastasis, " ACS AppliedMaterials&Interfaces, vol. 7, no. 51, pp. 28286-28293, 2015.
32. R. Kalluri and R. A. Weinberg, "The basics of epithelialmesenchymal transition, " The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420-1428, 2009.
33. Y. Lv, S. Zhao, J. Han, L. Zheng, Z. Yang, and L. Zhao, "Hypoxiainducible factor-1 induces multidrug resistance protein in colon cancer, " OncoTargets and Therapy, vol. 8, pp. 1941-1948, 2015.
34. E. A. Turley, M. Veiseh, D. C. Radisky, and M. J. Bissell, "Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression?" Nature Clinical Practice Oncology, vol. 5, no. 5, pp. 280-290, 2008.
35. H. Chen, A. Shen, Y. Zhang, et al., "Pien Tze Huang inhibits hypoxia-induced epithelial-mesenchymal transition in human colon carcinoma cells through suppression of the HIF-1 pathway, " Experimental and Therapeutic Medicine, vol. 7, no. 5, pp. 1237-1242, 2014.
36. Q. Dai, Q. Yin, L. Wei, et al., "Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells, " Molecular Carcinogenesis, 2015.
37. K. Zhao, X. Song, Y. Huang, et al., "Wogonin inhibits LPSinduced tumor angiogenesis via suppressing PI3K/Akt/NF-B signaling, " European Journal of Pharmacology, vol. 737, pp. 57-69, 2014.
38. H. Wang, L. Zhao, L.-T. Zhu, et al., "Wogonin reverses hypoxia resistance of human colon cancerHCT116 cells via downregulation of HIF-1 and glycolysis, by inhibiting PI3K/Akt signaling pathway, "Molecular Carcinogenesis, vol. 53, no. 1, pp. E107-E118, 2014.
39. G. Bellone, A. Carbone, C. Smirne, et al., "Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells, " The Journal of Immunology, vol. 177, no. 5, pp. 3448-3460, 2006.
40. B.-N. Lee, M. Follen, G. Rodriquez, et al., "Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions, " Cancer, vol. 107, no. 5, pp. 999-1007, 2006.
41. I. Perrot, D. Blanchard, N. Freymond, et al., "Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage, " The Journal of Immunology, vol. 178, no. 5, pp. 2763-2769, 2007.
42. L. A. Ormandy, A. Farber, T. Cantz, et al., "Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma, " World Journal of Gastroenterology, vol. 12, no. 20, pp. 3275-3282, 2006.
43. D. Gabrilovich, "Mechanisms and functional significance of tumour-induced dendritic-cell defects, " Nature Reviews Immunology, vol. 4, no. 12, pp. 941-952, 2004.
44. Y. Tian, X. Li, H. Li, Q. Lu, G. Sun, and H. Chen, "Astragalus mongholicus regulate the Toll-like-receptor 4 meditated signal transduction of dendritic cells to restrain stomach cancer cells, " African Journal of Traditional, Complementary and Alternative Medicines, vol. 11, no. 3, pp. 92-96, 2014.
45. J. E. Talmadge and D. I. Gabrilovich, "History of myeloidderived suppressor cells, " Nature Reviews Cancer, vol. 13, no. 10, pp. 739-752, 2013.
46. G. Schiavoni, L. Gabriele, and F. Mattei, "The tumor microenvironment: a pitch for multiple players, " Frontiers in Oncology, vol. 3, article 90, 2013.
47. R. Wang, Y. Li, W. Wang, M. Zhou, and Z. Cao, "Compound K suppresses myeloid-derived suppressor cells in a mouse model bearing CT26 colorectal cancer xenograft, " Nan Fang Yi Ke Da Xue Xue Bao, vol. 35, no. 5, pp. 748-752, 2015.
48. B. Ruffell, N. I. Affara, and L. M. Coussens, "Differential macrophage programming in the tumor microenvironment, " Trends in Immunology, vol. 33, no. 3, pp. 119-126, 2012.
49. B.-Z. Qian and J. W. Pollard, "Macrophage diversity enhances tumor progression and metastasis, " Cell, vol. 141, no. 1, pp. 39-51, 2010.
50. J. W. Pollard, "Trophic macrophages in development and disease, " Nature Reviews Immunology, vol. 9, no. 4, pp. 259-270, 2009.
51. G. Solinas, G. Germano, A. Mantovani, and P. Allavena, "Tumor-associatedmacrophages (TAM) as major players of the cancer-related inflammation, " Journal of Leukocyte Biology, vol. 86, no. 5, pp. 1065-1073, 2009.
52. S. F. Schoppmann, P. Birner, J. Stockl, et al., "Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis, " The American Journal of Pathology, vol. 161, no. 3, pp. 947-956, 2002.
53. H. Y. Tan, N. Wang, K. Man, S. W. Tsao, C. M. Che, and Y. Feng, "Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin, " Cell Death & Disease, vol. 6, no. 10, Article IDe1942, 2015.
54. S.-Q. Gong, W. Sun, M. Wang, and Y.-Y. Fu, "Role of TLR4 and TCR or BCR against baicalin-induced responses in T and B cells, " International Immunopharmacology, vol. 11, no. 12, pp. 2176-2180, 2011.
55. X. Qi, G. Liu, L. Qiu, X. Lin, and M. Liu, "Marine bromophenol bis(2, 3-dibromo-4, 5-dihydroxybenzyl) ether, represses angiogenesis inHUVEC cells and in zebrafish embryos via inhibiting theVEGF signal systems, " Biomedicine&Pharmacotherapy, vol. 75, pp. 58-66, 2015.
56. Y.-C. Hseu, S.-C. Chen, W.-H. Lin, et al., "Toona sinensis (leaf extracts) inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in vascular endothelial cells, " Journal of Ethnopharmacology, vol. 134, no. 1, pp. 111-121, 2011.
57. N. Ferrara, "Vascular endothelial growth factor: basic science and clinical progress, " Endocrine Reviews, vol. 25, no. 4, pp. 581-611, 2004.
58. C. I. M. Baeten, F. Hillen, P. Pauwels, A. P. de Bruine, and C. G. M. I. Baeten, "Prognostic role of vasculogenic mimicry in colorectal cancer, " Diseases of the Colon and Rectum, vol. 52, no. 12, pp. 2028-2035, 2009.
59. B. Sun, S. Zhang, D. Zhang, et al., "Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma, " Oncology Reports, vol. 16, no. 4, pp. 693-698, 2006.
60. M. Li, Y. Gu, Z. Zhang, et al., "Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma, " Pathology and Oncology Research, vol. 16, no. 2, pp. 259-266, 2010.
61. J.-M. Lu, Q. Yao, and C. Chen, "Ginseng compounds: an update on their molecular mechanisms and medical applications, " Current Vascular Pharmacology, vol. 7, no. 3, pp. 293-302, 2009.
62. D. F. Zeng, J. L. Wang, P. Y. Kong, C. Chang, J. Li, and J. Li, "Ginsenoside Rg3 inhibits HIF-1 and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways, " International Journal of Clinical and Experimental Pathology, vol. 7, no. 5, pp. 2172-2178, 2014.
63. N. Koonrungsesomboon, K. Na-Bangchang, and J. Karbwang, "Therapeutic potential and pharmacological activities of Atractylodes lancea (Thunb.) DC, " Asian Pacific Journal of Tropical Medicine, vol. 7, no. 6, pp. 421-428, 2014.
64. S. Wang, R. Cai, J. Ma, et al., "The natural compound codonolactone impairs tumor induced angiogenesis by downregulating BMP signaling in endothelial cells, " Phytomedicine, vol. 22, no. 11, pp. 1017-1026, 2015.
65. J.-M. Lin, L.-H. Wei, Y.-Q. Chen, et al., "Pien Tze Huang (β)-induced apoptosis in human colon cancer HT-29 cells is associated with regulation of the Bcl-2 family and activation of caspase 3, " Chinese Journal of IntegrativeMedicine, vol. 17, no. 9, pp. 685-690, 2011.
66. Q. Zhuang, F. Hong, A. Shen, et al., "Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model, " International Journal of Oncology, vol. 40, no. 5, pp. 1569-1574, 2012.
67. A.-L. Shen, F. Hong, L.-Y. Liu, et al., "Effects of Pien Tze Huang on angiogenesis in vivo and in vitro, " Chinese Journal of Integrative Medicine, vol. 18, no. 6, pp. 431-436, 2012.
68. A. Shen, F. Hong, L. Liu, et al., "Pien Tze Huang inhibits the proliferation of human colon carcinoma cells by arresting G1/S cell cycle progression, " Oncology Letters, vol. 4, no. 4, pp. 767-770, 2012.
69. A. Shen, J. Lin, Y. Chen, et al., "Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways, " Oncology Reports, vol. 30, no. 4, pp. 1701-1706, 2013.
70. A. Shen, Y. Chen, F. Hong, et al., "Pien TzeHuang suppresses IL-6-inducible STAT3 activation in human colon carcinoma cells through induction of SOCS3, " Oncology Reports, vol. 28, no. 6, pp. 2125-2130, 2012.
71. G. W. Yang, J. S. Jiang, and W. Q. Lu, "Ferulic acid exerts anti-angiogenic and anti-tumor activity by targeting fibroblast growth factor receptor 1-mediated angiogenesis, " International Journal of Molecular Sciences, vol. 16, no. 10, pp. 24011-24031, 2015.
72. W. Zheng, A. Aspelund, and K. Alitalo, "Lymphangiogenic factors, mechanisms, and applications, " The Journal of Clinical Investigation, vol. 124, no. 3, pp. 878-887, 2014.
73. S. Karaman and M. Detmar, "Mechanisms of lymphatic metastasis, " The Journal of Clinical Investigation, vol. 124, no. 3, pp. 922-928, 2014.
74. X. Kang, J. Kim, M. Deng, et al., "Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors, " Cell Cycle, vol. 15, no. 1, pp. 25-40, 2016.
75. Y. Kimura and M. Sumiyoshi, "Anti-tumor and anti-metastatic actions of wogonin isolated from Scutellaria baicalensis roots through anti-lymphangiogenesis, " Phytomedicine, vol. 20, no. 3-4, pp. 328-336, 2013.
76. Y.-Z. Fan, J.-Y. Fu, Z.-M. Zhao, and C.-Q. Chen, "Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro, " Hepatobiliary & Pancreatic Diseases International, vol. 6, no. 1, pp. 72-80, 2007.
77. Y.-Z. Fan, Z.-M. Zhao, J.-Y. Fu, C.-Q. Chen, and W. Sun, "Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo, " Hepatobiliary & Pancreatic Diseases International, vol. 9, no. 4, pp. 414-422, 2010.
78. C.-C. Yu, F.-Y. Ko, C.-S. Yu, et al., "Norcantharidin triggers cell death and DNA damage through S-phase arrest and ROSmodulated apoptotic pathways in TSGH 8301 human urinary bladder carcinoma cells, " International Journal of Oncology, vol. 41, no. 3, pp. 1050-1060, 2012.
79. S.-H. Kok, S.-J. Cheng, C.-Y. Hong, et al., "Norcantharidininduced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio, " Cancer Letters, vol. 217, no. 1, pp. 43-52, 2005.
80. Y.-P. Ho, K. K. W. To, S. C. F. Au-Yeung, X. Wang, G. Lin, and X. Han, "Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional chinesemedicine, with a platinummoiety, " Journal ofMedicinal Chemistry, vol. 44, no. 13, pp. 2065-2068, 2001.
81. J. A. Nagy, E. Vasile, D. Feng, et al., "Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis, " The Journal of Experimental Medicine, vol. 196, no. 11, pp. 1497-1506, 2002.
82. F. Raler, U. Voigt, S. Metz, P. Elsner, and S. Schliemann, "Fast-growing tumor of the eyelid, " Journal der Deutschen Dermatologischen Gesellschaft, vol. 14, no. 1, pp. 81-84, 2016.
83. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
84. V. Catalano, A. Turdo, S. Di Franco, F. Dieli, M. Todaro, and G. Stassi, "Tumor and its microenvironment: a synergistic interplay, " Seminars in Cancer Biology, vol. 23, no. 6, pp. 522-532, 2013.
85. S. Wang, X. Wu, M. Tan, et al., "Fighting fire with fire: poisonous Chinese herbalmedicine for cancer therapy, " Journal of Ethnopharmacology, vol. 140, no. 1, pp. 33-45, 2012.
86. F. He, H.-N. Wu, M.-Y. Cai, et al., "Inhibition of ovarian cancer cell proliferation by Pien Tze Huang via the AKT-mTOR pathway, " Oncology Letters, vol. 7, no. 6, pp. 2047-2052, 2014.
87. E. Hervouet, M. Cheray, F. M. Vallette, and P. Cartron, "DNA methylation and apoptosis resistance in cancer cells, " Cells, vol. 2, no. 3, pp. 545-573, 2013.
88. C.-M. Hsu, Y. Tsai, L. Wan, and F.-J. Tsai, "BufalininducesG2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells, " International Journal of Oncology, vol. 43, no. 1, pp. 338-348, 2013.
89. B. Wang, Q. Han, and Y. Zhu, "Oxymatrine inhibited cell proliferation by inducing apoptosis in human lung cancer A549 cells, " Bio-Medical Materials and Engineering, vol. 26, pp. S165-S172, 2015.
90. D. A. Liebermann, B. Hoffman, and D. Vesely, "p53 induced growth arrest versus apoptosis and its modulation by survival cytokines, " Cell Cycle, vol. 6, no. 2, pp. 166-170, 2007.
91. F. Liu, J.-G. Wang, S.-Y. Wang, Y. Li, Y.-P. Wu, and S.-M. Xi, "Antitumor effect and mechanism of Gecko on human esophageal carcinoma cell lines in vitro and xenografted sarcoma 180 in Kunming mice, "World Journal of Gastroenterology, vol. 14, no. 25, pp. 3990-3996, 2008.
92. L. Ma and W. Li, "Emodin inhibits LOVO colorectal cancer cell proliferation via the regulation of the Bcl-2/Bax ratio and cytochrome c, " Experimental and Therapeutic Medicine, vol. 8, no. 4, pp. 1225-1228, 2014.
93. R. M. Mohammad, I. Muqbil, L. Lowe, et al., "Broad targeting of resistance to apoptosis in cancer, " Seminars in Cancer Biology, vol. 35, supplement, pp. S78-S103, 2015.
94. P. Plastina, D. Bonofiglio, D. Vizza, et al., "Identification of bioactive constituents of Ziziphus jujube fruit extracts exerting antiproliferative and apoptotic effects in human breast cancer cells, " Journal of Ethnopharmacology, vol. 140, no. 2, pp. 325-332, 2012.
95. B. Wang, Q. Han, and Y. Zhu, "Oxymatrine inhibited cell proliferation by inducing apoptosis in human lung cancer A549 cells, " Bio-Medical Materials and Engineering, vol. 26, supplement 1, pp. S165-S172, 2015.
96. L. Chu, H. Zhao, J. Fang, et al., "The traditional Chinese medicinal formula BDL301 suppresses tumor growth by inhibiting STAT3 pathway and inducing apoptosis in colorectal cancer cells, " DNA and Cell Biology, vol. 34, no. 3, pp. 178-188, 2015.
97. X.-Y. Dang, L. Dong, H.-T. Shi, and B.-C. Zou, "Effects of serum containing Chinese medicine Sanpi Pingwei (γ) formula on proliferation and apoptosis of human SGC-7901 cells, " Chinese Journal of Integrative Medicine, vol. 19, no. 2, pp. 119-126, 2013.
98. N. Li, D. Zheng, J. Xue, et al., "Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest, " Experimental andTherapeuticMedicine, vol. 9, no. 5, pp. 1709-1718, 2015.
99. W. Liu, S. Y. Li, X. E. Huang, J. J. Cui, T. Zhao, and H. Zhang, "Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum, " Asian Pacific Journal of Cancer Prevention, vol. 13, no. 5, pp. 2409-2414, 2012.
100. Y.-L. Hsu, M.-H. Yen, P.-L. Kuo, et al., "San-Zhong-Kui-Jian-Tang, a traditional Chinese medicine prescription, inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis, " Biological & Pharmaceutical Bulletin, vol. 29, no. 12, pp. 2388-2394, 2006.
101. X. S. Chai, X. X. Zhang, and W. Y. Wu, "Xiaoji Decoction inhibited cell proliferation and induced apoptosis through Akt signaling pathway in human lung cancer A549 cells, " Chinese Journal of Integrative Medicine, vol. 20, no. 9, pp. 701-705, 2014.
102. S.-Y. Xi, Y.-H. Teng, Y. Chen, et al., "Jianpi Huayu Decoction inhibits proliferation in human colorectal cancer cells (SW480) by inducing G0/G1-phase cell cycle arrest and apoptosis, " Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 236506, 8 pages, 2015.
103. L. Zhang, W. Tian, S. Kim, W. Ding, Y. Tong, and S. Chen, "Arsenic sulfide, the main component of realgar, a traditional Chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo, " Drug Design Development and Therapy, vol. 9, pp. 79-92, 2015.
104. M. Qiao, S. Sheng, and A. B. Pardee, "Metastasis and AKT activation, " Cell Cycle, vol. 7, no. 19, pp. 2991-2996, 2008.
105. J. K. Beatty, A. Bhargava, and A. G. Buret, "Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection, " World Journal of Gastroenterology, vol. 20, no. 14, pp. 3976-3985, 2014.
106. Z. Liu, Z. Liu, X. Zhang, P. Xue, and H. Zhang, "RY10-4 suppressed metastasis ofMDA-MB-231 by stabilizing ECMand E-cadherin, " Biomedicine&Pharmacotherapy, vol. 68, no. 4, pp. 439-445, 2014.
107. Y. Zhang, J. Liu, J. Kou, J. Yu, and B. Yu, "DT-13 suppresses MDA-MB-435 cell adhesion and invasion by inhibiting MMP-2/9 via the p38 MAPK pathway, " Molecular Medicine Reports, vol. 6, no. 5, pp. 1121-1125, 2012.
108. X. Liu, R. Dong, Z. Jiang, et al., "MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition, " Tumor Biology, vol. 36, no. 6, pp. 4261-4269, 2015.
109. M. S. Tretiakova, J. Hart, M. T. Shabani-Rad, J. Zhang, and Z.-H. Gao, "Distinction of hepatocellular adenoma from hepatocellular carcinoma with and without cirrhosis using E-cadherin andmatrixmetalloproteinase immunohistochemistry, " Modern Pathology, vol. 22, no. 8, pp. 1113-1120, 2009.
110. M. Arechederra, N. Priego, A. Vazquez-Carballo, et al., "p38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: role in migration and invasion, " The Journal of Biological Chemistry, vol. 290, no. 7, pp. 4383-4397, 2015.
111. W. Li, C. Chen, S. M. Saud, et al., "Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment, " BMC Complementary and Alternative Medicine, vol. 14, article 153, 2014.
112. Y.-W. Chiu, T.-H. Lin, W.-S. Huang, et al., "Baicalein inhibits the migration and invasive properties of human hepatoma cells, " Toxicology and Applied Pharmacology, vol. 255, no. 3, pp. 316-326, 2011.
113. Y. Ohashi, Y. Tsuchiya, K. Koizumi, H. Sakurai, and I. Saiki, "Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model, " Oncology, vol. 65, no. 3, pp. 250-258, 2003.
114. D. S. Vinay, E. P. Ryan, G. Pawelec, et al., "Immune evasion in cancer: mechanistic basis and therapeutic strategies, " Seminars in Cancer Biology, vol. 35, supplement, pp. S185-S198, 2015.
115. J. B. Swann and M. J. Smyth, "Immune surveillance of tumors, " The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1137-1146, 2007.
116. J. W. Shay and I. B. Roninson, "Hallmarks of senescence in carcinogenesis and cancer therapy, " Oncogene, vol. 23, no. 16, pp. 2919-2933, 2004.
117. Q. Guo, J. Li, and H. Lin, "Effect and molecular mechanisms of traditional chinese medicine on regulating tumor immunosuppressive microenvironment, " BioMed Research International, vol. 2015, Article ID261620, 12 pages, 2015.
118. M. Campoli and S. Ferrone, "Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands, " Tissue Antigens, vol. 72, no. 4, pp. 321-334, 2008.
119. Y.-L. Li, B.-G. Sun, T. Xiang, Z.-X. Chen, and S.-J. Zhang, "Effect of invigorating spleen and detoxification decoction on MHC I/MHC II in spleen-deficiency liver cancer rats survival, " Journal of Chinese Medicinal Materials, vol. 37, no. 3, pp. 454-460, 2014.
120. M. Villa-Morales and J. Fernandez-Piqueras, "Targeting the Fas/FasL signaling pathway in cancer therapy, " Expert Opinion on Therapeutic Targets, vol. 16, no. 1, pp. 85-101, 2012.
121. E. Reichmann, "The biological role of the Fas/FasL system during tumor formation and progression, " Seminars in Cancer Biology, vol. 12, no. 4, pp. 309-315, 2002.
122. J. Li, G.-Z. Sun, H.-S. Lin, et al., "The herb medicine formula Yang Wei Kang Liu improves the survival of late stage gastric cancer patients and induces the apoptosis of human gastric cancer cell line through Fas/Fas ligand and Bax/Bcl-2 pathways, " International Immunopharmacology, vol. 8, no. 9, pp. 1196-1206, 2008.
123. M. Kedmi, A. Avigdor, and A. Nagler, "Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities, " Acta Haematologica, vol. 133, no. 2, pp. 129-135, 2014.
124. M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, "PD-1 and its ligands in tolerance and immunity, " Annual Review of Immunology, vol. 26, pp. 677-704, 2008.
125. J. R. Wang, J. Y. Wang, T. T. Zhang, and X. D. Cheng, "Regulate molecular expression of PD-1/PD-Ls by Astragalus polysaccharides on melanoma mice, " Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai, vol. 28, no. 5, pp. 74-79, 2014.
126. J. Gu, X. Fang, J. Hao, and X. Sha, "Reversal of P-glycoproteinmediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery, " Biomaterials, vol. 45, pp. 99-114, 2015.
127. J. C. Leighton Jr. and L. J. Goldstein, "P-glycoprotein in adult solid tumors: expression and prognostic significance, " Hematology/Oncology Clinics of North America, vol. 9, no. 2, pp. 251-273, 1995.
128. E. K. Fetisova, A. V. Avetisyan, D. S. Izyumov, M. V. Korotetskaya, B. V. Chernyak, and V. P. Skulachev, "Mitochondriatargeted antioxidant SkQR1 selectively protectsMDR(Pgp 170)-negative cells against oxidative stress, " FEBS Letters, vol. 584, no. 3, pp. 562-566, 2010.
129. W.-B. Li, Y. Li, C. Yu, and Y.-M. He, "Reversal of multidrug resistance by the Chinese medicine Yiqi Jianpi Huaji decoction and the mechanism of action in human gastric cancer SGC7901/VCR Cells, " Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 390812, 11 pages, 2015.
130. S. Y. Eid, M. Z. El-Readi, M. L. Ashour, and M. Wink, "Fallopia japonica, a natural modulator, can overcome multidrug resistance in cancer cells, " Evidence-Based Complementary and AlternativeMedicine, vol. 2015, Article ID868424, 8 pages, 2015.
131. F. Chen, M. Zhuang, C. Zhong, et al., "Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1 signaling pathway, " Oncology Reports, vol. 33, no. 1, pp. 457-463, 2015.
132. H. Sui, L.-H. Zhou, Y.-L. Zhang, et al., "Evodiamine suppresses ABCG2 mediated drug resistance by inhibiting p50/NF-B pathway in colorectal cancer, " Journal of Cellular Biochemistry, 2015.
133. C.-Z. Wang, X. Luo, B. Zhang, et al., "Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells, " Cancer Chemotherapy and Pharmacology, vol. 60, no. 1, pp. 69-79, 2007.
134. J. M. Llovet, S. Ricci, V. Mazzaferro, et al., "Sorafenib in advanced hepatocellular carcinoma, " The New England Journal of Medicine, vol. 359, no. 4, pp. 378-390, 2008.
135. B. Zhai and X.-Y. Sun, "Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma, " World Journal of Hepatology, vol. 5, no. 7, pp. 345-352, 2013.
136. B. Zhai, F. Hu, X. Jiang, et al., "Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma, " Molecular Cancer Therapeutics, vol. 13, no. 6, pp. 1589-1598, 2014.
137. B. Zhai, F. Hu, H. Yan, et al., "Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma: the role of endoplasmic reticulum stress, " PLoS ONE, vol. 10, no. 9, Article IDe0138485, 2015.
138. M. F. Clarke, J. E. Dick, P. B. Dirks, et al., "Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells, " Cancer Research, vol. 66, no. 19, pp. 9339-9344, 2006.
139. Y.-C. He, F.-L. Zhou, Y. Shen, D.-F. Liao, and D. Cao, "Apoptotic death of cancer stem cells for cancer therapy, " International Journal of Molecular Sciences, vol. 15, no. 5, pp. 8335-8351, 2014.
140. D. E. Costea, O. Tsinkalovsky, O. K. Vintermyr, A. C. Johannessen, and I. C. Mackenzie, "Cancer stem cells-new and potentially important targets for the therapy of oral squamous cell carcinoma, " Oral Diseases, vol. 12, no. 5, pp. 443-454, 2006.
141. Y. Chang, Y. Zhao, H. Zhan, X. Wei, T. Liu, and B. Zheng, "Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells, " Tumor Biology, vol. 35, no. 2, pp. 1075-1082, 2014.
142. E. R. Carlson, D. Oreadi, and J. M. McCoy, "Nevoid basal cell carcinoma syndrome and the keratocystic odontogenic tumor, " Journal ofOral andMaxillofacial Surgery, vol. 73, no. 12, pp. S77-S86, 2015.
143. W. Li, Q. Wang, Q. Su, et al., "Honokiol suppresses renal cancer cells metastasis Via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling, " Molecules and Cells, vol. 37, no. 5, pp. 383-388, 2014.
144. L. Wei, P. Chen, Y. Chen, et al., "Pien Tze Huang suppresses the stem-like side population in colorectal cancer cells, " Molecular Medicine Reports, vol. 9, no. 1, pp. 261-266, 2014.
145. M. A. Swartz, N. Iida, E. W. Roberts, et al., "Tumormicroenvironment complexity: emerging roles in cancer therapy, " Cancer Research, vol. 72, no. 10, pp. 2473-2480, 2012.
146. T. Yin, S. He, T. Ye, G. Shen, Y. Wan, and Y. Wang, "Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis, " Translational Oncology, vol. 7, no. 2, pp. 221-229, 2014.
147. C.-Y. Wu, L.-H. Yang, H.-Y. Yang, et al., "Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors, " Clinical Cancer Research, vol. 20, no. 3, pp. 644-657, 2014.
148. C. M. Zegers, N. H. Rekers, D. H. Quaden, et al., "Radiotherapy combined with the immunocytokine L19-IL2 provides longlasting antitumor effects, " Clinical Cancer Research, vol. 21, no. 5, pp. 1151-1160, 2015.
149. Q. Huang, F. Li, X. Liu, et al., "Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy, " Nature Medicine, vol. 17, no. 7, pp. 860-866, 2011.